Search Results
Search for other papers by Hathairat Rueangdetnarong in
Google Scholar
PubMed
Search for other papers by Rattanaporn Sekararithi in
Google Scholar
PubMed
Search for other papers by Thidarat Jaiwongkam in
Google Scholar
PubMed
Search for other papers by Sirinart Kumfu in
Google Scholar
PubMed
Search for other papers by Nipon Chattipakorn in
Google Scholar
PubMed
Search for other papers by Theera Tongsong in
Google Scholar
PubMed
Search for other papers by Phudit Jatavan in
Google Scholar
PubMed
Objective
The primary objective of this study was to compare the levels of oxidative stress biomarkers between pregnancies with gestational diabetes mellitus (GDM) and normoglycemic pregnancies.
Materials and methods
A prospective study was conducted on pregnant women at average risk for GDM. The participants were screened for GDM with glucose challenge test and confirmed by 100 g, 3-h oral glucose tolerance test and categorized into the control (non-GDM) and GDM groups. Maternal blood was collected from all participants at gestational age (GA) 24–28 weeks and early labor and fetal cord blood was collected for measurements of 8 Isoprostane (8Isop) (oxidative stress marker), TNF-α (inflammatory marker) and IL-10 (anti-inflammatory marker) and were followed up for maternal and neonatal outcomes.
Result
A total of 62 women, 30 in GDM and 32 in control group, met the inclusion criteria. At 24–28 weeks of gestation, maternal serum 8Isop and TNF-α levels were significantly higher in GDM group (P = 0.032 and P = 0.047), in spite of good glycemic control. At early labor, maternal 8Isop levels were significantly higher in GDM (P = 0.001). The biomarkers in the cord blood as well as maternal and neonatal outcomes in both groups were not significantly different.
Conclusion
GDM is significantly associated with inflammatory process when compared to normal pregnancy, as indicated by higher oxidative stress and apoptosis markers. However, such levels were not correlated with the pregnancy outcomes. An increase in oxidative stress could not be prevented by good glycemic control. Cord blood biomarker levels in pregnancy with GDM were not changed, suggesting that the placenta could be the barrier for the oxidative stress and cytokines.
Search for other papers by Panisa Hantrakun in
Google Scholar
PubMed
Search for other papers by Rattanaporn Sekararithi in
Google Scholar
PubMed
Search for other papers by Thidarat Jaiwongkam in
Google Scholar
PubMed
Search for other papers by Sirinart Kumfu in
Google Scholar
PubMed
Search for other papers by Chatree Chai-adisaksopha in
Google Scholar
PubMed
Search for other papers by Nipon Chattipakorn in
Google Scholar
PubMed
Search for other papers by Theera Tongsong in
Google Scholar
PubMed
Search for other papers by Phudit Jatavan in
Google Scholar
PubMed
Objectives
To evaluate the effect of metformin in improving platelet dysfunction in women with gestational diabetes mellitus (GDM).
Patients and methods
A randomized controlled trial was conducted on pregnant women diagnosed with GDM. Singleton low-risk pregnancies meeting the inclusion criteria were randomly allocated at 27–31 weeks to receive metformin and placebo through the rest of pregnancy. Thirty-seven and 39 cases were recruited into the metformin group and the placebo group, respectively. MPVs, P-selectin, and 8-isoprostane levels were determined at the time of allocation and 6 weeks after treatment. Obstetric and neonatal outcomes were also assessed.
Results
Most baseline characteristics of the two groups were comparable. The levels of P-selectin after 6 weeks of treatment were significantly higher in the metformin group (68.9 ± 14.4 vs 60.6 ± 11.3; P-value = 0.006), indicating more platelet activation. All of the obstetric and neonatal outcomes were comparable except that birth weight was significantly lower in the metformin group (3018 ± 364 g vs 3204 ± 393 g; P-value = 0.037).
Conclusion
Metformin, in addition to diet and lifestyle modifications, does not improve or worsen oxidative stress and platelet dysfunction in women with GDM. Nevertheless, metformin significantly reduces fetal weight in women with GDM, theoretically preventing macrosomia.
